June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
49 citations
,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
August 2025 in “JAAD International” Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
108 citations
,
January 2003 in “Fertility and Sterility” Flutamide may slightly improve hair loss in women, but finasteride does not work.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
1 citations
,
January 2021 in “Open Access Journal of Cancer & Oncology” Energy healing treatment improved flutamide's solubility and stability, potentially enhancing its effectiveness for prostate cancer.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
18 citations
,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
December 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Flutamide, an oral anti-androgen therapy, is effective in treating female pattern hair loss, even without systemic androgen excess.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
June 2018 in “The Journal of Sexual Medicine” Finasteride helps female-pattern hair loss.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.